{
    "clinical_study": {
        "@rank": "31687", 
        "acronym": "IPCL", 
        "arm_group": [
            {
                "arm_group_label": "ePID closed loop system using Insupatch", 
                "arm_group_type": "Experimental", 
                "description": "Insupatch activated at mealtimes"
            }, 
            {
                "arm_group_label": "ePID closed loop system without InsuPatch", 
                "arm_group_type": "Active Comparator", 
                "description": "InsuPatch will not be activated at mealtimes"
            }
        ], 
        "brief_summary": {
            "textblock": "This research study designed to look at how well adolescents' and young adults' blood sugars\n      can be controlled with a \"closed loop artificial pancreas\" using a continuous glucose\n      sensor, an insulin pump, and a computer program that automatically determines how much\n      insulin to give based on the glucose level.   The investigators will also study the effect\n      of wearing a small heating patch, the InsuPatch, at the site of insulin infusion, on the\n      ability of the closed loop system to control the blood sugar levels and to reduce the rise\n      in glucose levels after meals."
        }, 
        "brief_title": "Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, single-center, randomized crossover study evaluating the performance\n      of a closed-loop (CL) insulin delivery system using a subcutaneous glucose sensor and an\n      external insulin pump comparing the peak post-prandial glucose levels and the post-prandial\n      glucose AUC during either CL control alone or CL control with the InsuPatch in an inpatient\n      hospital research unit (HRU) setting.  The closed loop visit consists of approximately 67\n      hours over 4 days and 3 nights."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age 12-40 years\n\n          2. clinical diagnosis of type 1 diabetes\n\n          3. duration of type 1 diabetes \u2265 1 year\n\n          4. HbA1c \u2264 9 %\n\n          5. Treated with pump therapy for at least 3 months\n\n          6. Body weight > 40 kg\n\n        Exclusion Criteria:\n\n          1. Insulin resistant (defined as requiring > 1.5 units/kg/day at time of study\n             enrollment\n\n          2. Presence of any medical or psychiatric disorder that may interfere with subject\n             safety or study conduct\n\n          3. Use of any medications (besides insulin) known to blood glucose levels, including\n             oral or other systemic glucocorticoid therapy.  Inhaled, intranasal, or rectal\n             corticosteroid use is allowed along as not given within 4 weeks of admission.  Use of\n             topical glucocorticoids is allowable as long as affected skin area does not overlap\n             with study device sites.  Subjects using herbal supplements will be excluded, due to\n             the unknown effects of these supplements on glucose control\n\n          4. History of poor wound healing, heat sensitivity, or diminished skin integrity.\n\n          5. History of hypoglycemic seizure within last 3 months\n\n          6. Anemic (low hematocrit), or evidence of renal insufficiency (elevated serum\n             creatinine)\n\n          7. Female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy\n\n          8. Subjects unable to give consent / permission / assent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787318", 
            "org_study_id": "HIC # 1208010682"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ePID closed loop system using Insupatch", 
                    "ePID closed loop system without InsuPatch"
                ], 
                "description": "Insulin pump controlled by closed loop unit and algorithm", 
                "intervention_name": "ePID closed loop system", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "ePID closed loop system using Insupatch", 
                "description": "device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site", 
                "intervention_name": "InsuPatch", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06520"
                }, 
                "name": "Yale University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Stuart Weinzimer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes", 
        "overall_contact": {
            "email": "lori.carria@yale.edu", 
            "last_name": "Lori Carria, MS", 
            "phone": "203-737-3595"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Stuart Weinzimer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Peak post-prandial plasma glucose excursions after breakfast, lunch, and dinner on days #2 and #3. One day with InsuPatch activated and one day without InsuPatch activated", 
            "measure": "Peak Post-Prandial Glucose Excursions", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total Area Under Curve of the meal-related glucose excursion over target", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Nadir glucose levels following the meals", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Mean 24 hour glucose levels", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Mean daytime and nighttime glucose levels", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Peak post-prandial insulin levels following meals", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Area Under Curve meal-related insulin excursion following meals", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}